Back

Cytokinetics' aficamten meets dual endpoints in 36-week HCM trial

Verifying
  • Cytokinetics reported aficamten met both primary endpoints in symptomatic non-obstructive hypertrophic cardiomyopathy.
  • 53% of aficamten recipients responded across at least three domains, versus 13% receiving placebo.
  • Cytokinetics plans an FDA application in fourth-quarter 2026 after two medical-journal publications.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.